U.S. markets closed
  • S&P 500

    4,163.26
    -22.21 (-0.53%)
     
  • Dow 30

    34,077.63
    -123.04 (-0.36%)
     
  • Nasdaq

    13,914.77
    -137.58 (-0.98%)
     
  • Russell 2000

    2,232.00
    -30.67 (-1.36%)
     
  • Crude Oil

    63.47
    +0.09 (+0.14%)
     
  • Gold

    1,770.50
    -0.10 (-0.01%)
     
  • Silver

    25.86
    +0.02 (+0.09%)
     
  • EUR/USD

    1.2042
    +0.0062 (+0.52%)
     
  • 10-Yr Bond

    1.6010
    +0.0280 (+1.78%)
     
  • GBP/USD

    1.3988
    +0.0148 (+1.07%)
     
  • USD/JPY

    108.1470
    -0.6360 (-0.58%)
     
  • BTC-USD

    56,273.88
    +291.04 (+0.52%)
     
  • CMC Crypto 200

    1,273.66
    -25.30 (-1.95%)
     
  • FTSE 100

    7,000.08
    -19.45 (-0.28%)
     
  • Nikkei 225

    29,685.37
    +2.00 (+0.01%)
     

REFILE-UPDATE 1-Eli Lilly's antibody combination receives FDA emergency use authorization for COVID-19

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

(Corrects typographical error in first paragraph)

Feb 9 (Reuters) - Eli Lilly's combination antibodytherapy to fight COVID-19 has been granted emergency useauthorization by the U.S. Food and Drug Administration, Lillysaid on Tuesday.

Lilly's combination therapy of two antibodies, bamlanivimaband etesevimab, helped cut the risk of hospitalization and deathin COVID-19 patients by 70%, data from a late-stage trial showedin January.

Lilly said the therapy will be available immediately.

"There are 100,000 doses ready immediately and an additional150,000 doses will be available throughout the first quarter,"Lilly said in a statement.

The company said that in collaboration with Amgen,it plans to manufacture up to 1 million doses of etesevimab foradministration with bamlanivimab by mid-2021.

Lilly said the "therapy is authorized for the treatment ofmild to moderate COVID-19 in patients aged 12 and older who areat high risk for progressing to severe COVID-19 and/orhospitalization."

The FDA, separately, said bamlanivimab and etesevimab arenot authorized for patients hospitalized due to COVID-19 or whorequire oxygen therapy due to COVID-19.

Late last month, Lilly reported a fourth-quarter profit thattopped Wall Street estimates. It recorded $871.2million in quarterly sales of the COVID-19 therapy bamlanivimab,benefiting from the U.S. government's move to stock up on thedrug for emergency use.(Reporting by Kanishka Singh in Bengaluru; Editing by ChristianSchmollinger and Leslie Adler)